Pay in 4 interest-free payments of $6.80 Learn more
Ships within 48 hours · Estimated delivery Aug 11 - Aug 16
Conclusion GLP-1 receptor agonists represent a paradigm shift in obesity and diabetes treatment, demonstrating unprecedented efficacy across multiple health domains ^1^36
6 In another study of people without diabetes, Saxenda was more effective for weight loss than lifestyle interventions alone, and weight loss was sustained for more than two years
Currently, most insurance coverage for GLP-1 RAs is limited to patients with type 2 diabetes, although their use for cardiovascular risk reduction in non-diabetic patients continues to gain support from clinical evidence [21]
By distribution channel, the online/direct-to-consumer (DTC) segment is expected to expand at the fastest CAGR between 2026 and 2035
That is unusual, and worth weighing carefully against the company's short track record
US$ 20.68
US$ 27.80
US$ 28.81
US$ 26.31
US$ 22.88
US$ 28.71
US$ 24.10
US$ 20.32
